120 related articles for article (PubMed ID: 27805271)
1. Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
Hwang S; Woo Y; Kim M; Park HJ
Int J Dermatol; 2017 Feb; 56(2):e35-e37. PubMed ID: 27805271
[No Abstract] [Full Text] [Related]
2. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
[No Abstract] [Full Text] [Related]
3. A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone--reversible posterior lobe leukoencephalopathy.
Pandey R; Patel A; Shah S; Patel KM; Shah PM; Shukla SN; Parikh BJ; Anand A; Talati SS; Panchal H; Parikh S; Thrutthel S
Leuk Lymphoma; 2006 Jul; 47(7):1431-4. PubMed ID: 16923587
[No Abstract] [Full Text] [Related]
4. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
5. Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.
Das A; Sil A; Mishra V; Das NK
Indian J Pharmacol; 2014; 46(5):557-9. PubMed ID: 25298592
[TBL] [Abstract][Full Text] [Related]
6. Dermatologic side effects of thalidomide in patients with multiple myeloma.
Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV
J Am Acad Dermatol; 2003 Apr; 48(4):548-52. PubMed ID: 12664018
[TBL] [Abstract][Full Text] [Related]
7. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
Rajkumar SV; Gertz MA; Witzig TE
N Engl J Med; 2000 Sep; 343(13):972-3. PubMed ID: 11012329
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
[No Abstract] [Full Text] [Related]
9. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
Rasche L; Einsele H; Nitschmann S
Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
[No Abstract] [Full Text] [Related]
11. Thalidomide and dexamethasone for resistant multiple myeloma.
Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R
Br J Haematol; 2003 Jun; 121(5):768-71. PubMed ID: 12780791
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
[TBL] [Abstract][Full Text] [Related]
13. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdrè L; Palareti G; Masini L; Tura S; Baccarani M
Blood; 2002 Sep; 100(6):2272-3. PubMed ID: 12229885
[No Abstract] [Full Text] [Related]
14. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
Wölfler A; Bauer F; Zollner G; Weber K; Sill H; Linkesch W
Haematologica; 2003 Apr; 88(4):ELT12. PubMed ID: 12681989
[No Abstract] [Full Text] [Related]
15. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G
Blood; 2001 Sep; 98(5):1614-5. PubMed ID: 11520815
[TBL] [Abstract][Full Text] [Related]
18. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistant myeloma: phase II clinical study with low-dose thalidomide plus high-dose dexamethasone.
Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Montenora I; Turano E
J Chemother; 2004 Nov; 16 Suppl 5():90-3. PubMed ID: 15675489
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
